Effective drug delivery by PEGylated drug conjugates

Advanced Drug Delivery Reviews

Volumn 55, Issue 2, 2003, Pages 217-250

  Greenwald, Richard B ^a   Choe, Yun H ^a   McGuire, Jeffrey ^a   Conover, Charles D ^a  

^a Enzon Incorporated   (United States)

Author keywords

6 Mercaptopurine; Amphotericin B; Camptothecin; Daunorubicin, Ara C; Doxorubicin; Lysozyme; Paclitaxel; Poly (ethylene glycol); Prodrugs; Tripartate prodrugs

Indexed keywords

ESTERS; MOLECULAR WEIGHT; MOLECULES; PROTEINS; TUMORS; WATER;

ORGANIC DRUGS;

DRUG PRODUCTS;

AMPHOTERICIN B; ANTIBODY; ANTIBODY CONJUGATE; BENZYL DERIVATIVE; CAMPTOTHECIN; CARBONIC ACID DERIVATIVE; CREMOPHOR; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ESTER; ESTER DERIVATIVE; GEMCITABINE; MACROGOL; MERCAPTOPURINE; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; ORGANIC COMPOUND; PACLITAXEL; PEPTIDE; PRODRUG; PROTEIN; THIOL; WATER;

CIRCULATION; CONJUGATE; DISEASE MODEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; HYBRIDIZATION; IN VIVO STUDY; MOLECULAR SIZE; MOLECULAR WEIGHT; PRIORITY JOURNAL; REVIEW; SOLUBILITY; TIME;

ANIMALS; ANTIBODIES; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EXCIPIENTS; HUMANS; OLIGONUCLEOTIDES; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PRODRUGS; PROTEINS;

EID: 0037428969     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00180-1     Document Type: Article

References (133)

1. Hooftman G., Herman S., Schacht E. Review: Poly(ethylene glycol)s with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates. J. Bioact. Compat. Polymers. 11:1996;135-159.
2. Vandegriff K.D., McCarthy M., Rohlfs R.J., Winslow R.M. Colloid osmotic properties of modified hemoglobins: Chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys. Chem. 69:1997;23-30.
3. Harris J.M. Poly(ethylene glycol) Chemistry, Biotechnical and Biomedical Applications. 1992;Plenum Press, New York.
4. Roy H.K., DiBaise J.K., Black J., Karolski W.J., Ratashak A., Ansari S. FEBS Lett. 496:2001;143-146.
5. Toy P.H., Janda K.D. Soluble polymer-supported organic synthesis. Acc. Chem. Res. 33:2000;546-554.
6. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 6:1991;181-202.
7. Putnam D., Kopecek J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
8. Bernstein A., Hurwitz E., Maron R., Arnon R., Sela M., Wilchek M. Higher antitumor efficacy of Daunomycin when linked to dextran: In vivo and in vitro studies. J. Natl. Cancer Inst. 60:1978;379-384.
9. Danhauser-Ried S., Hausmann E., Schick H., Bender R., Dietzfelbinger H., Rastetter J., Hanauske A. Phase I clinical and pharmacokinetic trial of dextran conjugated Dox (AD-70, DOX-OXD). Invest. New Drugs. 11:1993;187-195.
10. Jultani A., Li C., Ozen M., Yadav M., Yu D., Wallace S., Pathak S. Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Anticancer Res. 17:1997;4269-4274.
11. Zunino F., Giuliani F., Savi G., Dasdia T., Gambetta R. Anti-tumor activity of Daunorubicin linked to poly-L-aspartic acid. Int. J. Cancer. 30:1982;465-470.
12. Lu Z.-R., Kopeèkova P., Wu Z., Kopeèk J. Functionalized semitelechelic poly[N-(2-hydroxypropyl) methacrylamide] for protein modification. Bioconjugate Chem. 9:1998;793-804.
13. Nucci M.L., Shorr R., Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Delivery Rev. 6:1991;133-151.
14. Abuchowski A., McCoy T.J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252:1977;3582-3586.
15. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Delivery Rev. 16:1995;157-182.
16. Greenwald R.B., Pendri A., Martinez A., Gilbert C., Bradley R. PEG thiazolidine-2-thione, a novel reagent for facile protein modification: Conjugation of bovine hemoglobin. Bioconjugate Chem. 7:1996;638-641.
17. Hershfield M.S. Adenosine deaminase deficiency: Clinical expression, molecular basis, and therapy. Semin. Hematol. 35:1998;291-298.
18. David S., Abuchowski A., Park Y.K., Davis F.F. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46:1981;649-652.
19. Ho P.P.K., Milkin E.B., Bobbitt J.L., Grinnan E.L., Burck P.J., Frank B.H., Boeck L.V.D., Squires R.W. Crystalline L-asparaginase from Escherichia coli B. J. Biol. Chem. 245:1970;3706-3715.
20. J. Kurtzberg, Asparaginase, in: J.F. Holland Jr, R.C. Bast Jr, D.L. Morton, E. Frei III, D.W. Kufe, R.R. Weichselbaum (Eds.), Cancer Medicine 4th Edition. Baltimore, MD, Lippincott Williams and Wilkins, V.I, Section XVI, Chemotherapeutic Agents (1997) pp. 1027-1036.
21. Wang Y., Youngster S., Bausch J., Zhang R., McNemar C., Wyss D.F. Identification of the major positional isomer of PEGylated IFN alpha-2b. Biochemistry. 39:2000;10634-10640.
22. Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., Jacobs S., Brassard D., Bausch J., Bordens R. Structural and biologic characterization of PEGylated recombinant IFN-α-2b. J. IFN Cytokine Res. 21:2001;1103-1115.
23. Wylie D.C., Voloch M., Lee S., Liu Y.H., Cannon-Carlson S., Cutler C., Pramanik B. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm. Res. 18:2001;1354-1360.
24. Somack R., Saifer M.G., Williams L.D. Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41, 000-72, 000 daltons). Free Radic. Res. Commun. 12-13:1991;553-562.
25. Zeuzem S., Heathcote J.E., Martin N., Nieforth K., Modi M. PegIFN alfa-2a (40 kDa) monotherapy: A novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs. 10:2001;2201-2213.
26. Martinez A., Pendri A., Greenwald R.B. Branched poly(ethylene glycol) linkers. Macromol. Chem. Phys. 198:1997;2489-2498.
27. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., Veronese F.M. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjugate Chem. 6:1995;62-69.
28. Morstyn G., Foote M., Walker T., Molineux G. Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol. 105:2001;151-155.
29. Holmes F.A., O'Shaughnessy J.A., Vukelja S., Jones S.E., Shogan J., Savin M., Glaspy J., Moore M., Meza L., Wiznitzer I., Neumann T.A., Hill L.R., Liang B.D. Blinded, randomized, multicenter study to evaluate single administration PEG filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 20:2002;727-731.
30. Yang J.C., Topalian S.L., Schwartzentruber D.J., Parkinson D.R., Marincola F.M. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 76:1995;687-694.
31. Trainer P.J., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342:2000;1171-1177.
32. Lustig R., Byhardt R., Diab S., Lillis P., Vigneri P., Kwiatek J., Viau A.T. A clinical phase IB study of PEG-hemoglobin in patients receiving palliative fractionated radiation for solid tumors. J. Clin. Oncology. 17:1999;1750.
33. Collen D., Sinnaeve P., Demarsin E., Moreau H., Maeyer M.D., Jespers L., Laroche Y., Van de Werf F. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Cancer. 102:2000;1766-1772.
34. Delgado C., Francis G.E., Fisher D. The uses and properties of PEG-linked proteins. Critical Rev. Ther. Drug Carrier Syst. 9:1992;249-304.
35. Katre N.V. The conjugation of proteins with polyethylene glycol and other polymers. Adv. Drug Delivery Rev. 10:1993;91-114.
36. Zalipsky S., Gilon C., Zilkha A. Attachment of drugs to polyethylene glycols. Eur. Polym. J. 19:1983;1177-1183.
37. Greenwald R.B., Pendri A., Bolikal D. Highly water soluble taxol derivatives. 7-Polyethylene glycol carbamates and carbonates. J. Org. Chem. 60:1995;331-336.
38. Enzon, Inc. Unpublished results.
39. Esslinger H.U., Haas S., Maurer R., Lassmann A., Dübbers K., Müller-Peltzer H. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Thromb. Haemost. 77:1997;911-919.
40. Yoo S.D., Jun H., Shin B.S., Lee H.S., Park M.O., Deluca P.D., Lee K.C. Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. Chem. Pharm. Bull. 48:2000;1921-1924.
41. Maeda M., Izuno Y., Kawasaki K., Kaneda Y., Mu Y., Tsutsumi Y., Lem K.W., Mayumi T. Amino acids and peptides, XXXII: A bifunctional poly (ethylene glycol) hybrid of fibronectin-related peptides. Biochem. Biophys. Res. Comm. 241:1997;595-598.
42. Chirila T.V., Rakoczy P.E., Garrett K.L., Lou X., Constable I.J. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials. 23:2002;321-342.
43. Jaschke A., Furste J.P., Cech D., Erdmann V.A. Automated incorporation of polyethylene glycol into synthetic oligonucleotides. Tetrahedron Lett. 34:1993;301-304.
44. Seelig B., Jaschke A. Site-specific modification of enzymatically synthesized RNA: Transcription initiation and Diels-Alder reaction. Tetrahedron Lett. 38:1997;7729-7732.
45. Kawaguchi T., Asakawa H., Tashiro Y., Juni K., Sueishi T. Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5′-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 18:1995;474-476.
46. Bonora G.M., Ivanova E., Zarytova V., Burcovich B., Veronese F.M. Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjugate Chem. 8:1997;793-797.
47. Jaschke A., Furste J.P., Nordhoff E., Hillenkamp F., Cech D., Erdmann V.A. synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. Nucleic Acids Res. 22:1994;4810-4817.
48. Burcovich B., Veronese F.M., Zarytova V., Bonora G.M. Branched polyethylene glycol (bPEG) conjugated antisense oligonucleotides. Nucleos. Nucleot. 17:1998;1567-1570.
49. Vorobjev P.E., Zarytova V.F., Bonora G.M. Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNAse H. Nucleos. Nucleot. 18:1999;2745-2750.
50. Rapozzi V., Cogoi S., Spessotto P., Risso A., Bonora G.M., Quadrifoglio F., Xodo L.E. Antigene effect in K562 cells of a PEG-conjugated triplex-forming oligonucleotide targeted to the bcrlabl oncogene. Biochemistry. 41:2002;502-510.
51. Lee L.S., Conover C., Shi C., Whitlow M., Filpula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjugate Chem. 10:1999;973-981.
52. Hurwitz E., Klapper L.N., Wilchek M., Yarden Y., Sela M. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol. Immunother. 49:2000;226-234.
53. 2 by amine-specific PEGylation with preserved bioactivity. Int. J. Pharmaceut. 198:2000;83-95.
54. Cheng T.-L., Chen B.-M., Chern J.-W., Wu M.-F., Roffler S.R. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjugate Chem. 11:2000;258-266.
55. Stella V.J., Charman W.N.A., Naringrekar V.H. Prodrugs, do they have advantages in clinical practice? Drugs. 29:1985;455-473.
56. Bundgaard H. Novel chemical approaches in prodrug design. Drugs of the Future. 16:1991;443-458.
57. Sinhababu A.K., Thakker D.R. Prodrugs of anticancer agents. Adv. Drug Delivery Rev. 19:1996;241-273.
58. Bundgaard H. The double prodrug concept and its applications. Adv. Drug Delivery Rev. 3:1989;39-65.
59. Vyas D.M. Paclitaxel (Taxol®) formulation and prodrugs. Farina V. The Chemistry and Pharmacology of Taxol and its Derivatives. 1995;Elsevier Science B.V.
60. Greenwald R.B., Pendri A., Bolikal D., Gilbert C.W. Highly water soluble taxol derivatives: 2-polyethyleneglycol esters as potential prodrugs. Bioorg. Med. Chem. Lett. 4:1994;2465-2470.
61. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., Martinez A. Drug delivery systems: Water soluble taxol 2-poly (ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39:1996;424-431.
62. w) of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and i.v. administration to rats. J. Biomed. Mat. Res. 21:1987;1341-1358.
63. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after i.v. administration to mice. J. Pharm. Sci. 83:1994;601-606.
64. Noguchi Y., Wun J., Duncan R., Strohalm R., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jap. J. Cancer Res. 89:1998;307-614.
65. Murakami Y., Tabata Y., Ikada Y. Tumor accumulation of poly (ethylene glycol) with different molecular weights after i.v. injection. Drug Del. 4:1997;23-32.
66. Kopecek J., Duncan R. Targetable polymeric prodrugs. J. Controlled Rel. 6:1987;315-327.
67. Conover C.D., Greenwald R.B., Pendri A., Gilbert C.W., Shum K.L. Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 42:1998;407-414.
68. A.J. Martinez, R.B. Greenwald, Method of preparing polyalkylene oxide carboxylic acids, U.S. Patent 5, 605, 976, 1997.
69. Knauf M.J., Bell D.P., Hirtzer P., Lou Z.P., Young J.D., Katre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers. J. Biol. Chem. 263:1988;15064-15070.
70. Maeda H., Seymour L., Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;351-362.
71. Potmesil M. Camptothecins: From bench research to hospital wards. Cancer Res. 54:1994;1431-1439.
72. Bedeschi A., Candiani I., Geroni C., Capolongo L. Water-soluble camptothecin derivatives. Drugs Future. 22:1997;1259-1266.
73. Wall M.E., Wani M.C. Camptothecin and taxol: Discovery to clinic-Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55:1995;753-760.
74. B.R. Vishnuvajjala, A. Garzon-Aburbeh, Water soluble prodrugs of camptothecin, U.S. Patent 4, 943, 579, 1990.
75. Wall M.E., Wani M.C., Nicholas W., Manikumar G., Tele C., Moore L., Truesdale A., Leitner P., Besterman J.M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem. 36:1993;2689-2700.
76. Greenwald R.B., Pendri A., Conover C., Gilbert C., Yang R., Xia J. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem. 39:1996;1938-1940.
77. Conover C.D., Pendri A., Lee C., Gilbert C.W., Shum K.L., Greenwald R.B. Camptothecin delivery systems: The antitumor activity of a camptothecin-20-O-polyethylene glycol ester transport form. Anti Cancer Res. 17:1997;3361-3368.
78. Zhao H., Lee C., Sai P., Choe Y.H., Boro M., Pendri A., Guan S., Greenwald R.B. 20-O-acylcamptothecin derivatives: Evidence for lactone stabilization. J. Org. Chem. 65:2000;4601-4606.
79. Ward R.S. The synthesis of lignans and neolignans. Chem. Soc. Rev. 11:1982;75-126.
80. Sackett D.L. Podophyllotoxin, steganicin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharmac. Ther. 59:1993;163-228.
81. Seidlova-Masinova V., Malinsky J., Santavy F. The biological effects of some podophyllin compounds and their dependence on chemical structure. J. Natl. Cancer Inst. 18:1957;359-371.
82. Greenspan E.M., Colsky J., Schoenbach E.B., Shear M.J. Response of patients with advanced neoplasms to the i.v. administration of α-peltatin. J. Natl. Cancer Inst. 14:1954;1257-1275.
83. Levy R.K., Hall I.H., Lee K.-H. Antitumor agents LXII: Synthesis and biological evaluation of podophyllotoxin esters and related derivatives. J. Pharm Sci. 72:1983;1158-1161.
84. Greenwald R.B., Conover C.D., Pendri A., Choe Y.H., Martinez A., Wu D., Guan S., Yao Z., Shum K.L. Drug delivery of anticancer agents: Water soluble 4-poly(ethylene glycol) derivatives of the lignan, podophyllotoxin. J. Control. Rel. 61:1999;281-294.
85. Pendri A., Conover C.D., Greenwald R.B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water-soluble prodrug. Anti-Cancer Drug Design. 13:1998;387-395.
86. Greenwald R.B., Pendri A., Conover C.D., Lee C., Choe Y.H., Gilbert C., Martinez A., Xia J., Wu D., Hsue M. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 6:1998;551-562.
87. Bernhard S.A., Berger A., Carter J.H., Katchalski E., Sela M., Shalitin Y. Co-operative effects of functional groups in peptides. I. Aspartyl-serine derivatives. J. Am. Chem. Soc. 84:1962;2421-2434.
88. Tadayoni B.M., Friden P.M., Walus L.R., Musso G.F. Synthesis, in vitro kinetics, and in vivo studies on protein conjugates of AZT: Evaluation as a transport system to increase brain delivery. Bioconjugate Chem. 4:1993;139-145.
89. Gogate U.S., Repta A.J., Alexander J. N-(acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I. Kinetics and mechanism of degradation in aqueous solutions. Int. J. Pharmaceut. 40:1987;235-248.
90. Fife T.H., DeMark B.R. Intramolecular nucleophilic aminolysis of aliphatic esters. cyclization of methyl 2-aminomethylbenzoate to phthalimidine. J. Am. Chem. Soc. 98:1976;6978-6982.
91. Saari W.S., Schwering J.E., Lyle P.A., Smith S.J., Englehardt E.L. Cyclization-activated prodrugs. Basic carbamates of 4-hydroxy anisole. J. Med. Chem. 33:1990;97-101.
92. Soyez H., Schacht E., Vanderkerken S. The crucial role of spacer groups in macromolecular prodrug design. Adv. Drug Delivery Rev. 21:1996;81-106.
93. Conover C.D., Greenwald R.B., Pendri A., Shum K.L. Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Design. 14:1999;499-506.
94. Han H., Oh D., Amidon G.L. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells over expressing a human peptide transporter. Pharmaceut. Res. 15:1998;1382-1386.
95. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys. Res. Commun. 250:1998;246-251.
96. Ochoa L., Tolcher A.W., Rizzo J., Schwartz G.H., Patnaik A., Hammond L., McCreery H., Denis L., Hidalgo M., Kwiatek J., McGuire J., Rowinsky E.K. A phase I study of PEG-camptothecin (PEG-CPT) in patients with advanced solid tumors: A novel formulation for an insoluble but active agent. J. Clin. Oncol. 19:2000;198a.
97. Deutsch H.M., Glinski J.A., Hernandez M., Haugwitz R.D., Narayan V., Suffness M., Zalkow L.H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32:1989;788-792.
98. Zhao Z., Kingston D.G.I., Crosswell A.R. Modified taxols, 6. Preparation of water-soluble prodrugs of taxol. J. Nat. Prod. 54:1991;1607-1611.
99. Matthew A.E., Mejillano M.R., Nath J.P., Himes R.H., Stella V.J. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem. 35:1992;145-151.
100. Dosio F., Arpicco S., Brusa P., Stella B., Cattel L. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: Preparation, characterization and pharmacokinetics. J. Controlled Rel. 76:2001;107-117.
101. Rodrigues P.C.A., Beyer U., Schumacher P., Roth T., Fiebig H.H., Unger C., Messori L., Orioli P., Paper E.H., Mulhaupt R., Kratz F. Acid-sensitive polyethylene glycol conjugates of doxorubicin: Preparation, in vitro efficacy and intracellular distribution. Bioorg. Med. Chem. 7:1999;2517-2524.
102. Greenwald R.B., Pendri A., Conover C.D., Zhao H., Choe Y.H., Martinez A., Shum K., Guan S. Drug delivery systems employing 1, 4-or 1, 6-elimination: Poly(ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 42:1999;3657-3667.
103. Greenwald R.B., Choe Y.H., Conover C.D., Zhao H., Shum K., Wu D., Royzen M. Drug delivery systems based on trimethyl lock lactonization: Poly(ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 43:2000;475-487.
104. Carl P.L., Chakravarty P.K., Katzenellenbogen J.A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 24:1981;479-480.
105. Denny W.A., Wilson W.R. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J. Pharm. Pharmacol. 50:1998;387-394.
106. Wakselman M. 1, 4- and 1, 6-eliminations from hydroxy and amino-substituted benzyl systems: Chemical and biochemical applications. Nouveau J. de Chemie. 7:1983;439-447.
107. Sedlak M., Buchta V., Kubicova L., Simunek P., Holcapek M., Kasparova P. Synthesis and characterization of a new amphotericin B-methoxypoly(ethylene glycol) conjugate. Bioorg. Med. Chem. Lett. 11:2001;2833-2835.
108. H. Zhao, C.D. Conover, P. Reddy, A. Martinez, C.B. Longley, R.B. Greenwald, The Utility of Polyethylene Glycol Conjugation to Create Prodrugs of Amphotericin B, National Biotechnology Conference, June 24-26 (2002) San Diego, CA.
109. S. Zimm, J.M. Collins, R. Riccardi, D. O'Neill, P.K. Narang, B. Chabner, D.G. Poplack, Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in a cute lymphoblastic leukemia being optimally delivered? N. Engl. J. Med. 308 (1983).
110. Y.H. Choe, S. Guan, R.B. Greenwald, PEG prodrugs of 6-mercaptopurine (6-MP) - II: Synthesis and in vitro studies, American Association for Cancer Research 93rd Annual Meeting (2002) April 6-10, San Francisco, CA.
111. Shan D., Nicholaou M.G., Borchardt R.T., Wang B. Prodrug strategies based on intramolecular cyclization reactions. J. Pharm. Sci. 86:1997;765-767.
112. Testa B., Mayer J.M. Design of intramolecularly activated prodrugs. Drug Metab. Rev. 30:1998;787-807.
113. Wang W., Jiang J., Ballard C.E., Wang B. Prodrug approaches to the improved delivery of peptide prodrugs. Curr. Pharm. Des. 5:1999;265-287.
114. Greenwald R.B., Choe Y.H., Conover C.D., Shum K., Wu D., Royzen M. Drug delivery systems based on trimethyl lock lactonization: Poly(ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 43:2000;475-487.
115. Hadfield A.F., Sartorelli A.C. The pharmacology of prodrugs of 5-flourouracil and 1-β-D-arabinofuranosylcytosine. Adv. Pharmacol. Chemother. 20:1984;21-67.
116. Wipf P., Li W. Prodrugs of ara-C. Drugs Future. 19:1994;49-54.
117. 4-behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res. 37:1977;2481-2486.
118. 4-substituted cytarabine derivatives as prodrugs. Pharmazie. 50:1995;382-387.
119. Ignoffo R.J. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. Am. J. Health-Syst. Pharm. 56:1999;2417-2428.
120. 4-Acyl poly (ethylene glycol) prodrugs of Ara-C. I. Efficacy in solid tumors. J. Control. Release. 79:2002;41-53.
121. Ranganathan D., Kurur S. Synthesis of totally chiral, multiple armed, poly glu and poly asp scaffoldings on a bifunctional adamantane core. Tetrahedron Lett. 38:1997;1265-1268.
122. 4-Acyl poly (ethylene glycol) prodrugs of Ara-C. II. Efficacy in ascites and solid tumors. J. Control. Release. 79:2002;55-70.
123. Nägele E., Schelhaas M., Kuder N., Waldmann H. Chemoenzymatic synthesis of N-Ras lipopeptides. J. Am. Chem. Soc. 120:1998;6889-6902.
124. Lee S., Greenwald R.B., McGuire J., Yang K., Shi C. Drug delivery systems employing 1, 6-elimination: Releasable poly(ethylene glycol) conjugates of proteins. Bioconjug. Chem. 12:2001;163-169.
125. Abuchowski A., van Es T., Palczuk N.C., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252:1977;3578-3581.
126. K. Yang, S. Lee, R.B. Greenwald, H. Zhao, C.D. Conover, H. Janjua, K.L. Shum, J. McGuire, Design and study of the linker controlled release of poly (ethylene glycol) conjugated protein, American Association of Pharmaceutical Scientists Conference: Pharmaceutics and Drug Delivery, April 22-24 (2002) Arlington, VA.
127. 5]-enkephalin (DPDPE). J. Pharmacol. Exp. Therap. 298:2001;848-856.
128. Lele B.S., Hoffman A.S. Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drug having hydrolysable PEG-anhydride-drug linkages. J. Control. Rel. 69:2000;237-248.
129. R.B. Greenwald, Y.H. Choe, US Patent 5, 965, 119, October 12, 1999.
130. R.B. Greenwald, A. Pendri, Y.H. Choe, US Patent 6, 180, 095 B1, January 30, 2001.
131. Tsunoda S., Ishikawa T., Yamamoto Y., Kamada H., Koizumi K., Matsui J., Tsutsumi Y., Hirano T., Mayumi T. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: A novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharm. Exp. Ther. 290:1999;368-372.
132. Suzawa T., Nagamura S., Saito H., Ohta S., Hanai N., Yamasaki M. Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation. Bioorg. Med. Chem. 8:2000;2175-2184.
133. Suzawa T., Nagamura S., Saito H., Ohta S., Hanai N., Kanazawa J., Okabe M., Yamasaki M. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly (ethylene glycol)-based cleavable linker. J. Controlled Release. 79:2002;229-242.